Washington, DC -- Specialty pharmaceutical firm Chase Pharmaceuticals has raised $500,000 in second round venture capital equity funding, according to an SEC filing.
Chase says that it is "engaged in the discovery and clinical development of improved treatments for neurologic and psychiatric disease."
The company's website indicates that it is currently completing a phase 2 trial of its lead program treatment candidate for patients with mild to moderate Alzheimer's disease.
Investors in the financing were not disclosed, nor was how the company intends to use the proceeds.
A total of 13 investors participated in the offering, which was an amended statement.